Barata, F.
Queiroga, H.
Teixeira, E.
Almodovar, T.
Soares, M.
Parente, B.
Mellidez, J.C.
Alves, P.
Antunes, A.
Funding for this research was provided by:
Roche
This article is maintained by: Elsevier
Article Title: Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Journal Title: Pulmonology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pulmoe.2020.08.007
Content Type: simple-article
Copyright: © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.